Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie R Earnshaw

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease|April 11, 2017
Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic modelMichele R Wilson, Jeetvan G Patel, Amber Coleman, et al.
Pharmacoeconomics|June 26, 2010
Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIVTeresa L Kauf, Raymond A Farkouh, Stephanie R Earnshaw, et al.
Journal of the American College of Surgeons|September 11, 2015
Economic Impact of Alvimopan Considering Varying Definitions of Postoperative IleusStephanie R Earnshaw, Teresa L Kauf, Cheryl McDade, et al.
The Journal of Infection|November 17, 2011
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The NetherlandsDavid R Strutton, Raymond A Farkouh, Stephanie R Earnshaw, et al.
Respiratory Medicine|November 18, 2008
Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPDStephanie R Earnshaw, Michele R Wilson, Anand A Dalal, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 2, 2016
Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of ChinaNingying Mao, Beth Lesher, Qifa Liu, et al.
Current Medical Research and Opinion|November 25, 2014
Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costsMelea A Ward, Gang Fang, Kristy L Richards, et al.
Journal of Health Economics and Outcomes Research|September 4, 2023
Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid LeukemiaMelea A Ward, Gang Fang, Kristy L Richards, et al.
Infectious Diseases and Therapy|April 10, 2020
Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective AnalysisMichele R Wilson, Matthew D Wasserman, Marie-Claude Breton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 9, 2008
Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuityJonathan C Javitt, Gergana P Zlateva, Stephanie R Earnshaw, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
International Journal of Chronic Obstructive Pulmonary Disease|April 11, 2017
Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic modelMichele R Wilson, Jeetvan G Patel, Amber Coleman, et al.
Pharmacoeconomics|June 26, 2010
Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIVTeresa L Kauf, Raymond A Farkouh, Stephanie R Earnshaw, et al.
Journal of the American College of Surgeons|September 11, 2015
Economic Impact of Alvimopan Considering Varying Definitions of Postoperative IleusStephanie R Earnshaw, Teresa L Kauf, Cheryl McDade, et al.
The Journal of Infection|November 17, 2011
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The NetherlandsDavid R Strutton, Raymond A Farkouh, Stephanie R Earnshaw, et al.
Respiratory Medicine|November 18, 2008
Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPDStephanie R Earnshaw, Michele R Wilson, Anand A Dalal, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 2, 2016
Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of ChinaNingying Mao, Beth Lesher, Qifa Liu, et al.
Current Medical Research and Opinion|November 25, 2014
Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costsMelea A Ward, Gang Fang, Kristy L Richards, et al.
Journal of Health Economics and Outcomes Research|September 4, 2023
Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid LeukemiaMelea A Ward, Gang Fang, Kristy L Richards, et al.
Infectious Diseases and Therapy|April 10, 2020
Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective AnalysisMichele R Wilson, Matthew D Wasserman, Marie-Claude Breton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 9, 2008
Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuityJonathan C Javitt, Gergana P Zlateva, Stephanie R Earnshaw, et al.
Pageof 4